Hannah Elizabeth Maier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hannah Elizabeth Maier has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Aubree Gordon
Department of Epidemiology, School of Public Health, University of Michigan
12 shared publications Angel Balmaseda
Sustainable Sciences Institute, Managua, Nicaragua
10 shared publicationsGuillermina Kuan
Sustainable Sciences Institute, Managua, Nicaragua
10 shared publicationsRoger Lopez
Sustainable Sciences Institute, Managua, Nicaragua
10 shared publicationsSergio Ojeda
Sustainable Sciences Institute, Managua, Nicaragua
10 shared publicationsMiguel Plazaola
Sustainable Sciences Institute, Managua, Nicaragua
8 shared publications
Latest Publications
- Open Access
- 9 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Infection-acquired protection against SARS-CoV-2 infection and clinical severity by number of prior infections
SARS-CoV-2 reinfections have increased since Omicron and are common. Yet, as we approach endemicity, the frequency, severity, and consequences of reinfections remain poorly understood. Using data from a household transmission study in Managua, Nicaragua (2020-2024), we evaluated protection conferred by one, two, and three+ prior infections and compared the severity of first, second, and third+ RT-PCR-confirmed SARS-CoV-2 infections. Compared to those with no prior infections, one, two, and three+ prior infections were associated with increasing protection from symptomatic infection, with incidence rate ratios of 0.39, (95% Confidence Interval [CI]: 0.26-0.61), 0.24 (95%CI: 0.13-0.42), and 0.20 (95%CI: 0.09-0.42), respectively. Among RT-PCR-confirmed infections, reinfections were associated with decreased severity; compared with first infections, second infections had 1.57 (95%CI: 1.15-2.16) times the proportion of subclinical disease and 0.65 (95%CI: 0.49-0.86) times the proportion of moderate/severe disease. Our findings suggest that protection generated from two prior infections may be stronger than one prior infection, although additional benefit beyond the second infection was not clearly observed. Together, our results suggest we are approaching an endemic phase of SARS-CoV-2 characterized by reduced severity relative to first infections, yet the burden remains high, underscoring the importance of maintaining immunity to manage ongoing disease.
- 9 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessInfection-acquired protection against SARS-CoV-2 infection and clinical severity by number of prior infections
SARS-CoV-2 reinfections have increased since Omicron and are common. Yet, as we approach endemicity, the frequency, severity, and consequences of reinfections remain poorly understood. Using data from a household transmission study in Managua, Nicaragua (2020-2024), we evaluated protection conferred by one, two, and three+ prior infections and compared the severity of first, second, and third+ RT-PCR-confirmed SARS-CoV-2 infections. Compared to those with no prior infections, one, two, and three+ prior infections were associated with increasing protection from symptomatic infection, with incidence rate ratios of 0.39, (95% Confidence Interval [CI]: 0.26-0.61), 0.24 (95%CI: 0.13-0.42), and 0.20 (95%CI: 0.09-0.42), respectively. Among RT-PCR-confirmed infections, reinfections were associated with decreased severity; compared with first infections, second infections had 1.57 (95%CI: 1.15-2.16) times the proportion of subclinical disease and 0.65 (95%CI: 0.49-0.86) times the proportion of moderate/severe disease. Our findings suggest that protection generated from two prior infections may be stronger than one prior infection, although additional benefit beyond the second infection was not clearly observed. Together, our results suggest we are approaching an endemic phase of SARS-CoV-2 characterized by reduced severity relative to first infections, yet the burden remains high, underscoring the importance of maintaining immunity to manage ongoing disease.
- Open Access
- 18 December 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (3) , e777-e781
Stunting Increases Influenza Virus Shedding Duration in Preschool/School-Aged Children
The role of undernutrition on influenza virus shedding is unclear. We assessed stunting, an indicator of chronic undernutrition, as a predictor of shedding duration in children in the Household Influenza Cohort Study, in Managua, Nicaragua. Stunted children, aged 3–9 years, shed influenza longer than their nonstunted peers. In sub-group analysis, associations were driven by H3N2 and influenza B (IB) infections. Analysis of cycle threshold (Ct) values showed slower clearance of IB viruses in stunted children. These findings suggest undernutrition may prolong influenza shedding, with implications for transmission dynamics and control strategies in low- and middle-income countries where stunting remains prevalent.
- 18 December 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (3) , e777-e781
Open AccessStunting Increases Influenza Virus Shedding Duration in Preschool/School-Aged Children
The role of undernutrition on influenza virus shedding is unclear. We assessed stunting, an indicator of chronic undernutrition, as a predictor of shedding duration in children in the Household Influenza Cohort Study, in Managua, Nicaragua. Stunted children, aged 3–9 years, shed influenza longer than their nonstunted peers. In sub-group analysis, associations were driven by H3N2 and influenza B (IB) infections. Analysis of cycle threshold (Ct) values showed slower clearance of IB viruses in stunted children. These findings suggest undernutrition may prolong influenza shedding, with implications for transmission dynamics and control strategies in low- and middle-income countries where stunting remains prevalent.
- Open Access
- 11 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10910
Anti-neuraminidase and anti-HA stalk antibodies reduce the susceptibility to and infectivity of influenza A/H3N2 virus
Immune responses against neuraminidase (NA) and hemagglutinin (HA) are critical for developing effective influenza vaccines, yet their role in influenza transmission remains unclear. We conducted household transmission studies in Managua, Nicaragua, to assess the impact of anti-NA and anti-HA antibodies induced by natural infection on influenza A/H3N2 susceptibility and infectivity. Using mathematical models capturing household transmission dynamics, we found that high pre-existing antibody levels against the HA head (>31, [95% CrI 13–67]), HA stalk (>35, [95% CrI 11–66]), and NA (>31, [95% CrI 12–68]) are associated with reduced susceptibility to infection (relative susceptibility: HA head, 0.63 [95% CrI 0.42–0.98]; HA stalk, 0.66 [95% CrI 0.44–0.99]; NA, 0.49 [95% CrI 0.30–0.76]). HA stalk (>58 [95% CrI: 47–70]) and NA (>27 [95% CrI: 15–43]) are associated with reduced infectivity (relative infectivity: NA, 0.55 [95% CrI: 0.32–0.98], HA stalk 0.53 [95% CrI: 0.27–0.97]). These findings suggest that influenza vaccines designed to elicit NA immunity in addition to HA immunity may not only enhance protection against infection but also reduce onward transmission.
- 11 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10910
Open AccessAnti-neuraminidase and anti-HA stalk antibodies reduce the susceptibility to and infectivity of influenza A/H3N2 virus
Immune responses against neuraminidase (NA) and hemagglutinin (HA) are critical for developing effective influenza vaccines, yet their role in influenza transmission remains unclear. We conducted household transmission studies in Managua, Nicaragua, to assess the impact of anti-NA and anti-HA antibodies induced by natural infection on influenza A/H3N2 susceptibility and infectivity. Using mathematical models capturing household transmission dynamics, we found that high pre-existing antibody levels against the HA head (>31, [95% CrI 13–67]), HA stalk (>35, [95% CrI 11–66]), and NA (>31, [95% CrI 12–68]) are associated with reduced susceptibility to infection (relative susceptibility: HA head, 0.63 [95% CrI 0.42–0.98]; HA stalk, 0.66 [95% CrI 0.44–0.99]; NA, 0.49 [95% CrI 0.30–0.76]). HA stalk (>58 [95% CrI: 47–70]) and NA (>27 [95% CrI: 15–43]) are associated with reduced infectivity (relative infectivity: NA, 0.55 [95% CrI: 0.32–0.98], HA stalk 0.53 [95% CrI: 0.27–0.97]). These findings suggest that influenza vaccines designed to elicit NA immunity in addition to HA immunity may not only enhance protection against infection but also reduce onward transmission.
- Open Access
- 21 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10305
Variant-specific antibody correlates of protection against SARS-CoV-2 Omicron symptomatic and overall infections
Vaccination and prior infection elicit neutralizing antibodies targeting SARS-CoV-2, yet the quantitative relationship between serum antibodies and infection risk against viral variants remains uncertain, particularly in underrepresented regions. We investigated the protective correlation of pre-exposure serum neutralizing antibody levels, employing a panel of SARS-CoV-2 pseudoviruses (Omicron BA.1, Omicron BA.2, and ancestral D614G), and Spike-binding antibody levels, with symptomatic BA.1 or BA.2 SARS-CoV-2 infections and overall infection, in 345 household contacts from a SARS-CoV-2 household cohort study in Nicaragua. A four-fold increase in homotypic-neutralizing (e.g., BA.1-neutralizing vs. BA.1 exposure) titers was correlated with protection from symptomatic infections (BA.1 protection: 28% [95%CI 12–42%]; BA.2 protection: 43% [20–62%]), and ancestral-neutralizing titers were also correlated with protection from either variant, but only at higher average levels than homotypic. Mediation analyses revealed that homotypic and D614G-neutralizing antibodies mediated protection from infection and symptomatic infection both from prior infection and vaccination. These findings underscore the importance of monitoring variant-specific antibody responses and highlight that antibodies targeting circulating strains may be more predictive of protection from infection. Nevertheless, ancestral-strain-neutralizing antibodies remain relevant as a correlate of protection. Our study emphasizes the need for continued efforts to assess antibody correlates of protection.
- 21 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10305
Open AccessVariant-specific antibody correlates of protection against SARS-CoV-2 Omicron symptomatic and overall infections
Vaccination and prior infection elicit neutralizing antibodies targeting SARS-CoV-2, yet the quantitative relationship between serum antibodies and infection risk against viral variants remains uncertain, particularly in underrepresented regions. We investigated the protective correlation of pre-exposure serum neutralizing antibody levels, employing a panel of SARS-CoV-2 pseudoviruses (Omicron BA.1, Omicron BA.2, and ancestral D614G), and Spike-binding antibody levels, with symptomatic BA.1 or BA.2 SARS-CoV-2 infections and overall infection, in 345 household contacts from a SARS-CoV-2 household cohort study in Nicaragua. A four-fold increase in homotypic-neutralizing (e.g., BA.1-neutralizing vs. BA.1 exposure) titers was correlated with protection from symptomatic infections (BA.1 protection: 28% [95%CI 12–42%]; BA.2 protection: 43% [20–62%]), and ancestral-neutralizing titers were also correlated with protection from either variant, but only at higher average levels than homotypic. Mediation analyses revealed that homotypic and D614G-neutralizing antibodies mediated protection from infection and symptomatic infection both from prior infection and vaccination. These findings underscore the importance of monitoring variant-specific antibody responses and highlight that antibodies targeting circulating strains may be more predictive of protection from infection. Nevertheless, ancestral-strain-neutralizing antibodies remain relevant as a correlate of protection. Our study emphasizes the need for continued efforts to assess antibody correlates of protection.
- Open Access
1 st , 2 nd , and 3 rd + SARS-CoV-2 infections: associations of prior infections with protection and severity
Since the emergence of the antigenically distinct Omicron variant, SARS-CoV-2 reinfections have increased and are common. Yet, as we approach endemicity, the frequency, severity, and consequences of reinfections remain poorly understood. Using data from a household transmission study in Managua, Nicaragua (2020-2024), we evaluated protection conferred by one, two, and three+ prior infections and compared the severity of first, second, and third+ RT-PCR-confirmed SARS-CoV-2 infections. In adults, compared to those with no prior infections, after adjusting for vaccination, one, two, and three+ prior infections were associated with increasing protection from symptomatic infection: 46%, (95% Confidence Interval [CI]: 32-57%), 69% (95%CI: 56-78%), and 77% (95%CI: 58-88%), respectively. Compared to first infections, second and third+ infections were associated with decreasing severity in adults, adjusted for vaccination; 35% (95%CI: 11-52%) and 42% (95%CI: 6-65%) less moderate/severe disease, and 152% (95%CI: 46-336%) and 243% (95%CI: 82-545%) more subclinical disease, respectively.
Open Access1 st , 2 nd , and 3 rd + SARS-CoV-2 infections: associations of prior infections with protection and severity
Since the emergence of the antigenically distinct Omicron variant, SARS-CoV-2 reinfections have increased and are common. Yet, as we approach endemicity, the frequency, severity, and consequences of reinfections remain poorly understood. Using data from a household transmission study in Managua, Nicaragua (2020-2024), we evaluated protection conferred by one, two, and three+ prior infections and compared the severity of first, second, and third+ RT-PCR-confirmed SARS-CoV-2 infections. In adults, compared to those with no prior infections, after adjusting for vaccination, one, two, and three+ prior infections were associated with increasing protection from symptomatic infection: 46%, (95% Confidence Interval [CI]: 32-57%), 69% (95%CI: 56-78%), and 77% (95%CI: 58-88%), respectively. Compared to first infections, second and third+ infections were associated with decreasing severity in adults, adjusted for vaccination; 35% (95%CI: 11-52%) and 42% (95%CI: 6-65%) less moderate/severe disease, and 152% (95%CI: 46-336%) and 243% (95%CI: 82-545%) more subclinical disease, respectively.
- Open Access
Comparative Analysis of SARS-CoV-2 Antibody Responses across Global and Lesser-Studied Vaccines
Few data are available on antibody response for some SARS-CoV-2 vaccines, and there is a lack of ability to compare vaccine responses in the same population. This cross-sectional study conducted in Nicaragua examines the SARS-CoV-2 antibody responses in individuals, previously exposed to high infection rates who have received various vaccines. The vaccines under comparison include well-known ones like Pfizer (BNT162b2) and AstraZeneca (ChAdOx1-S), alongside less-studied vaccines including Soberana (Soberana 02), Abdala (CIGB-66), and Sputnik V/Sputnik Light. Overall, 3195 individuals participated, with 2862 vaccinated and 333 unvaccinated. We found that 95% of the unvaccinated were seropositive, with much lower titers than the vaccinated. Among the vaccinated, we found that Soberana recipients mounted the highest anti-spike response (mean difference (MD) = 36,498.8 [20,312.2, 52,685.5]), followed by Abdala (MD = 25,889.9 [10,884.1, 40,895.7]), BNT162b2 (MD = 12,967.2 [7543.7, 18,390.8]) and Sputnik with AstraZeneca as the reference group, adjusting for age, sex, vaccine status, days after last dose, and self-reported COVID-19. In addition, we found that subjects with complete vaccination series had higher antibody magnitude than those with incomplete series. Overall, we found no evidence of waning in the antibody magnitude across vaccines. Our study supports the conclusion that populations with high infection rates still benefit substantially from vaccination.
Open AccessComparative Analysis of SARS-CoV-2 Antibody Responses across Global and Lesser-Studied Vaccines
Few data are available on antibody response for some SARS-CoV-2 vaccines, and there is a lack of ability to compare vaccine responses in the same population. This cross-sectional study conducted in Nicaragua examines the SARS-CoV-2 antibody responses in individuals, previously exposed to high infection rates who have received various vaccines. The vaccines under comparison include well-known ones like Pfizer (BNT162b2) and AstraZeneca (ChAdOx1-S), alongside less-studied vaccines including Soberana (Soberana 02), Abdala (CIGB-66), and Sputnik V/Sputnik Light. Overall, 3195 individuals participated, with 2862 vaccinated and 333 unvaccinated. We found that 95% of the unvaccinated were seropositive, with much lower titers than the vaccinated. Among the vaccinated, we found that Soberana recipients mounted the highest anti-spike response (mean difference (MD) = 36,498.8 [20,312.2, 52,685.5]), followed by Abdala (MD = 25,889.9 [10,884.1, 40,895.7]), BNT162b2 (MD = 12,967.2 [7543.7, 18,390.8]) and Sputnik with AstraZeneca as the reference group, adjusting for age, sex, vaccine status, days after last dose, and self-reported COVID-19. In addition, we found that subjects with complete vaccination series had higher antibody magnitude than those with incomplete series. Overall, we found no evidence of waning in the antibody magnitude across vaccines. Our study supports the conclusion that populations with high infection rates still benefit substantially from vaccination.
- Open Access
- 23 January 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (2) , ofae039
Reduction in Long COVID Symptoms and Symptom Severity in Vaccinated Compared to Unvaccinated Adults
The impact of vaccination prior to infection on postacute sequelae of coronavirus disease 2019 (COVID-19, PASC), also known as long COVID, remains unclear. Here we assess the protective effect of vaccination on long COVID in a community-based setting. The Immunity Associated with SARS-CoV-2 (IASO) study is an ongoing prospective cohort of working adults that began in October 2020. Participants are actively followed for severe acute respiratory syndrome coronavirus 2 infection. We compared the prevalence of symptoms and symptom severity in vaccinated compared to unvaccinated cases. Our primary definition of long COVID was the presence of symptoms at 90 days postinfection; 30 days postinfection was also examined. Overall, by 90 days postinfection, 13% of cases had long COVID, with 27% of unvaccinated cases and 8% of vaccinated cases reporting long COVID (relative risk [RR], 0.31 [95% confidence interval {CI}, .22–.42]). Vaccination was also associated with significantly lower average severity scores at all timepoints (eg, relative severity at 90 days postinfection: −2.70 [95% CI, −1.68 to −3.73]). In the pre-Omicron era, 28% of unvaccinated cases and 18% of vaccinated cases reported long COVID (P = .07), and vaccinated cases reported less severe symptoms including less difficulty breathing (P = .01; 90-day RR, 0.07). Vaccinated cases had lower prevalence of long COVID and reduced symptom severity.
- 23 January 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (2) , ofae039
Open AccessReduction in Long COVID Symptoms and Symptom Severity in Vaccinated Compared to Unvaccinated Adults
The impact of vaccination prior to infection on postacute sequelae of coronavirus disease 2019 (COVID-19, PASC), also known as long COVID, remains unclear. Here we assess the protective effect of vaccination on long COVID in a community-based setting. The Immunity Associated with SARS-CoV-2 (IASO) study is an ongoing prospective cohort of working adults that began in October 2020. Participants are actively followed for severe acute respiratory syndrome coronavirus 2 infection. We compared the prevalence of symptoms and symptom severity in vaccinated compared to unvaccinated cases. Our primary definition of long COVID was the presence of symptoms at 90 days postinfection; 30 days postinfection was also examined. Overall, by 90 days postinfection, 13% of cases had long COVID, with 27% of unvaccinated cases and 8% of vaccinated cases reporting long COVID (relative risk [RR], 0.31 [95% confidence interval {CI}, .22–.42]). Vaccination was also associated with significantly lower average severity scores at all timepoints (eg, relative severity at 90 days postinfection: −2.70 [95% CI, −1.68 to −3.73]). In the pre-Omicron era, 28% of unvaccinated cases and 18% of vaccinated cases reported long COVID (P = .07), and vaccinated cases reported less severe symptoms including less difficulty breathing (P = .01; 90-day RR, 0.07). Vaccinated cases had lower prevalence of long COVID and reduced symptom severity.
- 20 July 2022
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 387 (6) , 568-570
Protection Associated with Previous SARS-CoV-2 Infection in Nicaragua
The course of the current pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will be determined in part by the quality and durability of protective immunity induced by previous infection, vaccination, or both, as well as by the severity of illness in persons with some level of immunity.1,2 From March 2020 through October 2021 in the Household Influenza Cohort Study (HICS) study, we followed 2353 participants, ranging in age from newborn infants to elderly persons up to 94 years of age, in 437 households in Nicaragua for the presence of SARS-CoV-2 infection ( Figure 1A ). The study was approved by the institutional review boards at the Nicaraguan Ministry of Health, the University of Michigan, and the University of California, Berkeley. All the participants (or their parents or guardians if they were under the age of 18 years) provided written informed consent; children who were 6 years of age or older also provided assent.
- 20 July 2022
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 387 (6) , 568-570
Protection Associated with Previous SARS-CoV-2 Infection in Nicaragua
The course of the current pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will be determined in part by the quality and durability of protective immunity induced by previous infection, vaccination, or both, as well as by the severity of illness in persons with some level of immunity.1,2 From March 2020 through October 2021 in the Household Influenza Cohort Study (HICS) study, we followed 2353 participants, ranging in age from newborn infants to elderly persons up to 94 years of age, in 437 households in Nicaragua for the presence of SARS-CoV-2 infection ( Figure 1A ). The study was approved by the institutional review boards at the Nicaraguan Ministry of Health, the University of Michigan, and the University of California, Berkeley. All the participants (or their parents or guardians if they were under the age of 18 years) provided written informed consent; children who were 6 years of age or older also provided assent.
- Open Access
SARS-CoV-2 infection-induced immunity and the duration of viral shedding: results from a Nicaraguan household cohort study
Background: Much of the world’s population has been infected with SARS-CoV-2. Thus, infection-induced immunity will play a critical role in future SARS-CoV-2 transmission. We investigated the impact of immunity from prior infection on viral shedding duration and viral load. Methods: We conducted a household cohort study in Managua, Nicaragua with an embedded transmission study that closely monitors participants regardless of symptom status. Real-time reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assays (ELISAs) were used to measure infections and seropositivity, respectively. Blood samples were collected in Feb/March and Oct/Nov 2020 and 2021, and surrounding household intensive monitoring periods. We used accelerated failure time models to compare shedding times. Participants vaccinated ≥14 days prior to infection were excluded from primary analyses. Results: There were 600 RT-PCR-confirmed SARS-CoV-2 infections between May 1, 2020 and March 10, 2022 with ELISA data prior to infection. Prior infection was associated with 48% shorter shedding times, event time ratio (ETR) 0.52 (95% CI: 0.39-0.69, mean shedding: 13.7 vs 26.4 days). A 4-fold higher anti-SARS-CoV-2 spike titer was associated with 17% shorter shedding (ETR 0.83, 95% CI: 0.78-0.90). Similarly, maximum viral loads (lowest CT) were lower for previously infected individuals (mean CT 29.8 vs 28.0, p = 4.02×10 −3 ). Shedding was shorter in previously infected adults and children ≥10 years, but not in children 0-9 years; there was little difference in CT levels for previously infected vs naïve adults above age 60. Conclusions: Prior infection-induced immunity was associated with shorter viral shedding and lower viral loads.
Open AccessSARS-CoV-2 infection-induced immunity and the duration of viral shedding: results from a Nicaraguan household cohort study
Background: Much of the world’s population has been infected with SARS-CoV-2. Thus, infection-induced immunity will play a critical role in future SARS-CoV-2 transmission. We investigated the impact of immunity from prior infection on viral shedding duration and viral load. Methods: We conducted a household cohort study in Managua, Nicaragua with an embedded transmission study that closely monitors participants regardless of symptom status. Real-time reverse-transcription polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assays (ELISAs) were used to measure infections and seropositivity, respectively. Blood samples were collected in Feb/March and Oct/Nov 2020 and 2021, and surrounding household intensive monitoring periods. We used accelerated failure time models to compare shedding times. Participants vaccinated ≥14 days prior to infection were excluded from primary analyses. Results: There were 600 RT-PCR-confirmed SARS-CoV-2 infections between May 1, 2020 and March 10, 2022 with ELISA data prior to infection. Prior infection was associated with 48% shorter shedding times, event time ratio (ETR) 0.52 (95% CI: 0.39-0.69, mean shedding: 13.7 vs 26.4 days). A 4-fold higher anti-SARS-CoV-2 spike titer was associated with 17% shorter shedding (ETR 0.83, 95% CI: 0.78-0.90). Similarly, maximum viral loads (lowest CT) were lower for previously infected individuals (mean CT 29.8 vs 28.0, p = 4.02×10 −3 ). Shedding was shorter in previously infected adults and children ≥10 years, but not in children 0-9 years; there was little difference in CT levels for previously infected vs naïve adults above age 60. Conclusions: Prior infection-induced immunity was associated with shorter viral shedding and lower viral loads.
- Open Access
The Nicaraguan Pediatric Influenza Cohort Study, 2011-2019: influenza incidence, seasonality, and transmission
Background Children account for a large portion of global influenza burden and transmission, and a better understanding of influenza in children is needed to improve prevention and control strategies. Methods To examine the incidence and transmission of influenza we conducted a prospective community-based study of children aged 0-14 years in Managua, Nicaragua between 2011 and 2019. Participants were provided with medical care through study physicians and symptomatic influenza was confirmed by RT-PCR. Wavelet analyses were used to examine seasonality. Generalized growth models (GGMs) were used to estimate effective reproduction numbers. Results From 2011-2019, 3,016 children participated, with an average of ∼1,800 participants per year and median follow-up time of 5 years per child, and 48.3% of the cohort in 2019 had been enrolled their entire lives. The overall incidence rates per 100 person-years were 14.5 symptomatic influenza cases (95%CI: 13.9-15.1) and 1.0 influenza-associated ALRI case (95%CI: 0.8-1.1). Symptomatic influenza incidence peaked at age 9-11 months. Infants born during peak influenza circulation had lower incidence in the first year of their lives. The mean effective reproduction number was 1.2 (range 1.02-1.49), and we observed significant annual patterns for influenza and influenza A, and a 2.5-year period for influenza B. Conclusions This study provides important information for understanding influenza epidemiology and informing influenza vaccine policy. These results will aid in informing strategies to reduce the burden of influenza. Summary In this long-running influenza cohort, we found a substantial incidence of RT-PCR-confirmed influenza, and report by subtype/lineage. Infants born during influenza epidemics were protected from infection that first year. The mean effective reproduction number across years was 1.2.
Open AccessThe Nicaraguan Pediatric Influenza Cohort Study, 2011-2019: influenza incidence, seasonality, and transmission
Background Children account for a large portion of global influenza burden and transmission, and a better understanding of influenza in children is needed to improve prevention and control strategies. Methods To examine the incidence and transmission of influenza we conducted a prospective community-based study of children aged 0-14 years in Managua, Nicaragua between 2011 and 2019. Participants were provided with medical care through study physicians and symptomatic influenza was confirmed by RT-PCR. Wavelet analyses were used to examine seasonality. Generalized growth models (GGMs) were used to estimate effective reproduction numbers. Results From 2011-2019, 3,016 children participated, with an average of ∼1,800 participants per year and median follow-up time of 5 years per child, and 48.3% of the cohort in 2019 had been enrolled their entire lives. The overall incidence rates per 100 person-years were 14.5 symptomatic influenza cases (95%CI: 13.9-15.1) and 1.0 influenza-associated ALRI case (95%CI: 0.8-1.1). Symptomatic influenza incidence peaked at age 9-11 months. Infants born during peak influenza circulation had lower incidence in the first year of their lives. The mean effective reproduction number was 1.2 (range 1.02-1.49), and we observed significant annual patterns for influenza and influenza A, and a 2.5-year period for influenza B. Conclusions This study provides important information for understanding influenza epidemiology and informing influenza vaccine policy. These results will aid in informing strategies to reduce the burden of influenza. Summary In this long-running influenza cohort, we found a substantial incidence of RT-PCR-confirmed influenza, and report by subtype/lineage. Infants born during influenza epidemics were protected from infection that first year. The mean effective reproduction number across years was 1.2.